Drug Profile
Etrasimod - Pfizer
Alternative Names: APD-334; Etrasimod arginine - Pfizer; PF-07915503; VELSIPITYLatest Information Update: 14 Mar 2024
Price :
$50
*
At a glance
- Originator Arena Pharmaceuticals
- Developer Arena Pharmaceuticals; Everest Medicines; Pfizer
- Class 3-ring heterocyclic compounds; Acetic acids; Amino acids; Anti-inflammatories; Benzene derivatives; Cyclopentanes; Ethers; Fluorinated hydrocarbons; Indoles; Skin disorder therapies; Small molecules
- Mechanism of Action Sphingosine 1 phosphate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Ulcerative colitis
- Phase II/III Atopic dermatitis; Crohn's disease
- Phase II Alopecia areata; Eosinophilic oesophagitis
- Discontinued Inflammatory bowel diseases; Primary biliary cirrhosis; Pyoderma gangrenosum
Most Recent Events
- 14 Mar 2024 Launched for Ulcerative colitis in USA (PO), before March 2024
- 10 Mar 2024 Preregistration for Ulcerative colitis (In adults) in Macau (PO)
- 10 Mar 2024 Pharmaceutical Administration Bureau of the Macau Special Administrative Region accepts NDA for Etrasimod for Ulcerative colitis for review